Etanercept for the treatment of non-radiographic axial spondyloarthritis.

about

Tumor Necrosis Factor Alpha Overexpression Induces Mainly Osteoclastogenesis at the Vertebral Site.

P2860

Q47830081-3F45513A-BE42-4FFE-861B-439AC1538FED

P2860

Etanercept for the treatment of non-radiographic axial spondyloarthritis.

Item

http://www.wikidata.org/entity/Q38703849

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Etanercept for the treatment of non-radiographic axial spondyloarthritis.

@en

type

Item

label

Etanercept for the treatment of non-radiographic axial spondyloarthritis.

@en

prefLabel

Etanercept for the treatment of non-radiographic axial spondyloarthritis.

@en

P1476

Etanercept for the treatment of non-radiographic axial spondyloarthritis.

@en

P2093

Valeria Rios Rodriguez

http://www.w3.org/2001/XMLSchema#string

P2860

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

Six months open label trial of leflunomide in active ankylosing spondylitis

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

Clinical considerations for biosimilar antibodies.

Consistently Good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial.

Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

P304

493-500

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/1744666X.2016.1144472

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Denis Poddubnyy

P577

2016-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26788837

http://www.w3.org/2001/XMLSchema#string

Etanercept for the treatment of non-radiographic axial spondyloarthritis.

about

P2860

P2860

Etanercept for the treatment of non-radiographic axial spondyloarthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698